India’s Sun Pharma has signed an agreement to take full control of Israeli generic drugmaker Taro Pharmaceutical Industries, taking it into private hands.
Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication.